Replies to post #377636 on Innovation Pharmaceuticals Inc (IPIX)

[petemantx]

You’ve basically bought into the BP scheme of keeping the SP low so value of company must be low. I am at complete odds with your thinking.

Revenue potential be damned, only look at the current financials. Ridiculous IMO

[MackG]

With successful trial results of B vs. Covid-19 and the many other indications it addresses, and with consideration of the history of clinical trial results to date for both Brilacidin and Kevetrin, potential suitors of IPIX will be baseing buyout offers on realistic modeling of future revenue streams. A buyout price will have little to do with current financials and current share price. The markets these two drugs addresses are massive and so too will be the profitability of the company that is successful in acquiring IPIX. You'll be pleasantly surprised at the valuation. IMO.

[loanranger]

"a company with $400 million invested"

How's that?
Not saying it's wrong necessarily, but how did you arrive at it?

[xoc]

In 2015 you said"My WAG is $20 within 30 trading days after announcement of the first partner/license. However broad or regional the agreement, it will be a billion dollar deal and will de-risk all other trials thr
ough fully funding everything else in the pipeline. That alone is worth adding another $10 a share. Then there is the added value of uplisting; $50 by 2017 is probably too low. ;-)"

Why the current pessimism on share price potential? The current sticker price does not even come close to reflecting the value of a potential panantiviral and at the least a potential covid treatment, new MRSA antibiotic with great antibiotic potential and antibiofilm potential . An anti inflammatory with GI and radiation induced oral mucositis potential. We also have kevetrin a drug that can likely modulate p53 in a multitude of cancers and could a major new chemotherapeutic agent. In 2015 price per share was a lot higher but likewise even then price per share did not reflect value.